A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2)
2025-04-22
عنوان الدراسة
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2)
داعم الدراسة
Pharvaris Netherlands B.V.
دواء الدراسة
Deucrictibant
رقم بروتوكول الدراسة
PHA022121-C303
حالة الدراسة
Ongoing
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
2/3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。